Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Seeks Eye Care Leadership With Full, $50 Billion Alcon Takeover

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis pays $28.1 billion for a further 52 percent stake in Alcon, seeking full control with a further offer to buy out minority shareholders.

You may also be interested in...



With 100% Alcon Ownership, Novartis Forms New Eye Care Unit

Novartis reaches agreement to buy the part of Alcon it doesn't already own for $12.9 billion, ending months of squabbling with Alcon minority shareholders.

With 100% Alcon Ownership, Novartis Forms New Eye Care Unit

Novartis reaches agreement to buy the part of Alcon it doesn't already own for $12.9 billion, ending months of squabbling with Alcon minority shareholders.

As Alcon Shareholders Fight Back, Will Novartis Sweeten Its Merger Offer?

As the Swiss drug giant builds a massive ophthalmology franchise, Alcon minority shareholders are pushing for a better deal.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070178

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel